Veracyte, Inc. VCYT NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

72/100

4/7 Pass

SharesGrow Intrinsic Value

Ha habido 50 transacciones internas recientes registradas para Veracyte, Inc. (VCYT), incluyendo 7 compras y 42 ventas. El total de compras internas fue valorado en RSU Award y el total de ventas internas en $11.45M.

Internos destacados con actividad reciente incluyen Haas Kevin Richard, Stapley Marc, Wygant Jonathan. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.

Operaciones de Insiders — VCYT

Fecha	Nombre	Cargo	Tipo de Transacción	Acciones	Precio Promedio	Valor	Acciones en Propiedad
2026-03-24	Haas Kevin Richard	Officer	Desconocido	-	-	-	-
2026-03-06	Stapley Marc	Chief Executive Officer	Concesión de RSU	92,099	-	-	449,653
2026-03-06	Wygant Jonathan	VP, Chief Accounting Officer	Concesión de RSU	10,525	-	-	45,434
2026-03-06	Febbo Phillip G.	Chief Scientific & Med Officer	Concesión de RSU	29,603	-	-	146,949
2026-03-06	Chambers Rebecca	Chief Financial Officer	Concesión de RSU	36,181	-	-	167,377
2026-03-06	Mcguire Annie	SVP, General Counsel	Concesión de RSU	32,892	-	-	127,598
2026-03-06	Leite John	Chief Commercial Officer-clia	Concesión de RSU	36,181	-	-	143,761
2026-03-04	Stapley Marc	Chief Executive Officer	Venta Informativa	26,279	$36.28	$953.37K	357,554
2026-03-04	Chambers Rebecca	Chief Financial Officer	Venta Informativa	13,941	$36.33	$506.46K	131,196
2026-03-04	Mcguire Annie	SVP, General Counsel	Venta Informativa	1,664	$36.34	$60.47K	94,706
2026-03-04	Leite John	Chief Commercial Officer-clia	Venta Informativa	5,260	$35.19	$185.08K	107,580
2026-03-02	Stapley Marc	Chief Executive Officer	Retención Fiscal de RSU	19,455	$36.01	$700.57K	403,077
2026-03-02	Wygant Jonathan	VP, Chief Accounting Officer	Retención Fiscal de RSU	3,006	$36.01	$108.25K	34,909
2026-03-02	Febbo Phillip G.	Chief Scientific & Med Officer	Venta Informativa	13,425	$36.16	$485.43K	117,346
2026-03-02	Chambers Rebecca	Chief Financial Officer	Retención Fiscal de RSU	7,234	$36.01	$260.5K	149,537
2026-03-02	Mcguire Annie	SVP, General Counsel	Retención Fiscal de RSU	6,902	$36.01	$248.54K	101,364
2026-03-02	Leite John	Chief Commercial Officer-clia	Retención Fiscal de RSU	7,517	$36.01	$270.69K	112,840
2026-02-26	Stapley Marc	Chief Executive Officer	Retención Fiscal de RSU	35,841	$38.75	$1.39M	422,532
2026-02-26	Febbo Phillip G.	Chief Scientific & Med Officer	Retención Fiscal de RSU	24,486	$38.75	$948.83K	136,806
2026-02-26	Chambers Rebecca	Chief Financial Officer	Retención Fiscal de RSU	12,049	$38.75	$466.9K	156,771
2026-02-26	Mcguire Annie	SVP, General Counsel	Retención Fiscal de RSU	10,867	$38.75	$421.1K	108,266
2026-02-26	Leite John	Chief Commercial Officer-clia	Retención Fiscal de RSU	8,905	$38.75	$345.07K	120,357
2025-12-16	Mcguire Annie	SVP, General Counsel	Venta Informativa	100	$43.68	$4.37K	67,760
2025-12-05	Eastham Karin	Director	Ejercicio de Opciones (Venta)	10,000	$7.94	$79.4K	-
2025-12-04	Stapley Marc	Chief Executive Officer	Venta Informativa	3,220	$47.35	$152.46K	318,603
2025-12-04	Chambers Rebecca	Chief Financial Officer	Venta Informativa	4,741	$47.25	$224.01K	109,496
2025-12-04	Mcguire Annie	SVP, General Counsel	Venta Informativa	702	$47.51	$33.35K	78,499
2025-12-04	Leite John	Chief Commercial Officer-clia	Venta Informativa	1,278	$47.51	$60.72K	82,113
2025-12-02	Stapley Marc	Chief Executive Officer	Retención Fiscal de RSU	7,914	$46.16	$365.31K	326,271
2025-12-02	Wygant Jonathan	VP, Chief Accounting Officer	Retención Fiscal de RSU	1,325	$46.16	$61.16K	37,420
2025-12-02	Febbo Phillip G.	Chief Scientific & Med Officer	Retención Fiscal de RSU	2,955	$46.16	$136.4K	89,486
2025-12-02	Chambers Rebecca	Chief Financial Officer	Retención Fiscal de RSU	3,384	$46.16	$156.21K	122,774
2025-12-02	Mcguire Annie	SVP, General Counsel	Retención Fiscal de RSU	3,052	$46.16	$140.88K	79,921
2025-12-02	Leite John	Chief Commercial Officer-clia	Retención Fiscal de RSU	2,900	$46.16	$133.86K	83,391
2025-11-25	Jones Evan/ Fa	Director	Venta Informativa	1,106	$50.25	$55.58K	29,362
2025-11-25	Leite John	Chief Commercial Officer-clia	Venta Informativa	2,808	$50.00	$140.4K	86,291
2025-11-20	Holstein Jens	Director	Venta Informativa	1,460	$43.21	$63.09K	27,199
2025-11-10	Wygant Jonathan	VP, Chief Accounting Officer	Venta Informativa	5,102	$42.33	$215.98K	38,745
2025-11-07	Wygant Jonathan	VP, Chief Accounting Officer	Venta Informativa	5,818	$40.21	$233.93K	43,847
2025-11-05	Jones Evan/ Fa	Director	Ejercicio de Opciones (Venta)	10,000	$5.28	$52.8K	-
2025-11-05	Eastham Karin	Director	Venta Informativa	9,674	$40.02	$387.19K	13,554
2025-11-05	Chambers Rebecca	Chief Financial Officer	Venta Informativa	7,000	$41.00	$287K	126,158
2025-11-05	Mcguire Annie	SVP, General Counsel	Venta Informativa	6,466	$40.00	$258.64K	82,973
2025-10-28	Wygant Jonathan	VP, Chief Accounting Officer	Concesión de RSU	2,886	-	-	49,665
2025-10-06	Febbo Phillip G.	Chief Scientific & Med Officer	Venta Informativa	8,349	$36.02	$300.71K	92,441
2025-10-01	Epstein Robert S	Director	Ejercicio de Opciones (Venta)	10,000	$7.94	$79.4K	-
2025-10-01	Mcguire Annie	SVP, General Counsel	Venta Informativa	2,160	$35.00	$75.61K	89,439
2025-10-01	Leite John	Chief Commercial Officer-clia	Venta Informativa	2,539	$35.00	$88.87K	89,099
2025-09-19	Mcguire Annie	SVP, General Counsel	Venta Informativa	2,283	$33.69	$76.92K	91,599
2025-09-04	Stapley Marc	Chief Executive Officer	Venta Informativa	7,667	$30.41	$233.13K	334,185

■ Informativa — transacción en mercado abierto (más significativa) ■ No informativa (compra) — premio, ejercicio de opción, conversión ■ No informativa (venta) — retención fiscal, venta de adjudicación ■ Neutral — regalo, fideicomiso, vencimiento